MANAGEMENT OF DRUG INTERACTIONS IN COLON CANCER PATIENTS

tezcan, songül

doi:10.33483/jfpau.1039307

MANAGEMENT OF DRUG INTERACTIONS IN COLON CANCER PATIENTS

Songül TEZCAN (Marmara Üniversitesi Eczacılık Fakültesi Klinik Eczacılık Anabilim Dalı, İstanbul, Türkiye)

Ankara Üniversitesi Eczacılık Fakültesi Dergisi

9 2

Yıl: 2022 Cilt: 46 Sayı: 2 Sayfa Aralığı: 537 - 550 Metin Dili: İngilizce DOI: 10.33483/jfpau.1039307 İndeks Tarihi: 07-09-2022

MANAGEMENT OF DRUG INTERACTIONS IN COLON CANCER PATIENTS

Öz:

Objective: Colon cancer is the third most common cancer type globally and usually occurs at advanced ages. Since the risk of comorbid diseases may also increase with age, colon cancer patients have an increased risk of polypharmacy. Hypertension, chronic obstructive pulmonary disease, diabetes, and cardiovascular disease are the frequently seen comorbidities in cancer patients. Patients who are elderly, have comorbid conditions, and are taking two or more medications are at higher risk for drug-drug interactions (DDIs). Additionally, cancer patients frequently use many drugs such as supportive care drugs for the treatment of side effects of cytotoxic drugs. DDIs may cause therapeutic failure or potentially serious adverse events. determination and evaluation of DDI levels identify the most suitable rational therapy for cancer patients. Result and Discussion: This study has reviewed the drugs used to treat colon cancer (Capecitabine, Fluorouracil, Irinotecan, Oxaliplatin, Bevacizumab, Ziv-Aflibercept, Nivolumab, Pembrolizumab, Ramucirumab, Regorafenib, Larotrectinib, Dabrafenib, Trametinib, Trifluridine and tipiracil, and Encorafenib) and determined the possible drug-drug interactions. This study will help the pharmacists and clinicians to evaluate possible interactions.

Anahtar Kelime:

KOLON KANSERI HASTALARINDA İLAÇ ETKİLEŞİMLERİNİN YÖNETİMİ

Öz:

Amaç: Kolon kanseri, dünya çapında en yaygın üçüncü kanser türüdür ve genellikle ileri yaşlarda ortaya çıkar. Yaşla birlikte komorbid hastalık riski de artabileceğinden, kolon kanseri hastalarının polifarmasi riski artmıştır. Hipertansiyon, kronik obstrüktif akciğer hastalığı, diyabet ve kardiyovasküler hastalık, kanser hastalarında sık görülen komorbiditelerdir. Yaşlı, komorbid rahatsızlıkları olan ve iki veya daha fazla ilaç alan hastalar, ilaç-ilaç etkileşimleri (İİE) için daha yüksek risk altındadır. Ayrıca kanser hastaları, sitotoksik ilaçların yan etkilerinin tedavisi için sıklıkla destekleyici bakım ilaçları gibi birçok ilacı kullanmaktadır. İİE'ler terapötik başarısızlığa veya potansiyel olarak ciddi yan etkilere neden olabilir. İİE düzeylerinin belirlenmesi ve değerlendirilmesi, kanser hastaları için en uygun akılcı tedavinin sağlanmasında yardımcı olmaktadır. Sonuç ve Tartışma: Bu çalışmada, kolon kanseri tedavisinde kullanılan ilaçlar (Kapesitabin, Fluorourasil, irinotecan, oksaliplatin, bevasizumab, ziv-aflibersept, nivolumumab, pembrolizumab, ramusirumab, regorafenib, larotrektinib, dabrafenib, trametinib, trifluridin ve tipirasil ve enkorafenib) incelenmiş ve olası ilaç etkileşimleri belirlenmiştir. Bu çalışma eczacıların ve klinisyenlerin olası etkileşimleri değerlendirmesine yardımcı olacaktır.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Derleme Erişim Türü: Erişime Açık

1. Laban, A.A., Birand, N., Chukwunyere, U., Abdi, A., Basgut, B. (2021). Evaluation of drug-drug interactions in cancer patients treated at a university hospital in North Cyprus using two interaction databases. Nigerian Journal of Clinical Practice, 24(7), 1067-1071. [CrossRef]
2. Lavan, A.H., O'Mahony, D., Buckley, M., O'Mahony, D., Gallagher, P. (2019). Adverse drug reactions in an oncological population: prevalence, predictability, and preventability. The Oncologist, 24(9), e968-e977. [CrossRef]
3. Montané, E., Castells, X. (2021). Epidemiology of drug-related deaths in European hospitals: a systematic review and meta-analysis of observational studies. British Journal of Clinical Pharmacology, 87(10), 3659-3671. [CrossRef]
4. Ismail, M., Khan, S., Khan, F., Noor, S., Sajid, H., Yar, S., Rasheed, I. (2020). Prevalence and significance of potential drug-drug interactions among cancer patients receiving chemotherapy. BMC Cancer, 20(1), 335. [CrossRef]
5. Capecitabine. In: Lexicomp online [database on the Internet). Hudson [OH): Lexicomp, Inc.; 2021 [cited 18 Feb 2021). Available from: http://online.lexi.com. Subscription required to view.
6. Medscape Web site. (2022). Retrieved April 17, 2022, from https://reference.medscape.com/ drug/xeloda-capecitabine-342211 .Accessed Date: 17.04.2022
7. Fluorouracil. In: Lexicomp online [database on the Internet). Hudson [OH): Lexicomp, Inc.; 2021 [cited 18 Feb 2021). Available from: http://online.lexi.com. Subscription required to view.
8. Medscape Web site. (2022). Retrieved April 17, 2022, from https://reference.medscape.com/drug/adrucil-fluorouracil-342092#3 .Accessed Date: 17.04.2022
9. Ramírez, J., House, L.K., Karrison, T.G., Janisch, L.A., Turcich, M., Salgia, R., Ratain, M.J., Sharma, M.R. (2019). Prolonged pharmacokinetic interaction between capecitabine and a CYP2C9 substrate, celecoxib. Journal of Clinical Pharmacology, 59(12), 1632-1640. [CrossRef]
10. Vayalil, R.K., Shetty, K.J., Mateti, U.V. (2018). Assessment of potential drug–drug interactions in an oncology unit of a tertiary care teaching hospital. Indian Journal of Medical and Paediatric Oncology, 39, 436-42. [CrossRef]
11. Salvador-Martín, S., García-González, X., García, M.I., Blanco, C., García-Alfonso, P., Robles, L., Grávalos, C., Pachón, V., Longo, F., Martínez, V., Sanjurjo-Sáez, M., López-Fernández, L.A. (2018). Clinical utility of ABCB1 genotyping for preventing toxicity in treatment with irinotecan. Pharmacological Research, 136, 133-139. [CrossRef]
12. Kehrer, D.F., Mathijssen, R.H., Verweij, J., de Bruijn, P., Sparreboom, A. (2002). Modulation of irinotecan metabolism by ketoconazole. Journal of Clinical Oncology: Official journal of the American Society of Clinical Oncology, 20(14), 3122-3129. [CrossRef]
13. Richards, S., Umbreit, J.N., Fanucchi, M.P., Giblin, J., Khuri, F. (2003). Selective serotonin reuptake inhibitor-induced rhabdomyolysis associated with irinotecan. Southern Medical Journal, 96(10), 1031-1033. [CrossRef]
14. Berg, A.K., Buckner, J.C., Galanis, E., Jaeckle, K.A., Ames, M.M., Reid, J.M. (2015). Quantification of the impact of enzyme-inducing antiepileptic drugs on irinotecan pharmacokinetics and SN-38 exposure. Journal of Clinical Pharmacology, 55(11), 1303-1312. [CrossRef]
15. Corona, G., Vaccher, E., Sandron, S., Sartor, I., Tirelli, U., Innocenti, F., Toffoli, G. (2008). Lopinavir-ritonavir dramatically affects the pharmacokinetics of irinotecan in HIV patients with Kaposi's sarcoma. Clinical Pharmacology and Therapeutics, 83(4), 601-606. [CrossRef]
16. Javle, M.M., Cao, S., Durrani, F.A., Pendyala, L., Lawrence, D.D., Smith, P.F., Creaven, P. J., Noel, D.C., Iyer, R.V., Rustum, Y.M. (2007). Celecoxib and mucosal protection: translation from an animal model to a phase i clinical trial of celecoxib, irinotecan, and 5-fluorouracil. Clinical Cancer Research: An official journal of the American Association for Cancer Research, 13(3), 965-971. [CrossRef]
17. van der Bol, J.M., Loos, W.J., de Jong, F.A., van Meerten, E., Konings, I.R., Lam, M.H., de Bruijn, P., Wiemer, E.A., Verweij, J., Mathijssen, R.H. (2011). Effect of omeprazole on the pharmacokinetics and toxicities of irinotecan in cancer patients: a prospective cross-over drug-drug interaction study. European Journal of Cancer (Oxford, England: 1990), 47(6), 831-838. [CrossRef]
18. de Man, F.M., Goey, A., van Schaik, R., Mathijssen, R., Bins, S. (2018). Individualization of Irinotecan treatment: a review of pharmacokinetics, pharmacodynamics, and pharmacogenetics. Clinical Pharmacokinetics, 57(10), 1229-1254. [CrossRef]
19. Engels, F.K., de Jong, F.A., Sparreboom, A., Mathot, R.A., Loos, W.J., Kitzen, J.J., de Bruijn, P., Verweij, J., Mathijssen, R.H. (2007). Medicinal cannabis does not influence the clinical pharmacokinetics of irinotecan and docetaxel. The Oncologist, 12(3), 291-300. [CrossRef]
20. Fujita, K., Matsumoto, N., Ishida, H., Kubota, Y., Iwai, S., Shibanuma, M., Kato, Y. (2019). Decreased disposition of anticancer drugs predominantly eliminated via the liver in patients with renal failure. Current Drug Metabolism, 20(5), 361-376. [CrossRef]
21. Jansman, F.G., Idzinga, F.S., Smit, W.M., de Graaf, J.C., Coenen, J.L., Sleijfer, D.T., Brouwers, J.R. (2005). Classification and occurrence of clinically significant drug interactions with irinotecan and oxaliplatin in patients with metastatic colorectal cancer. Clinical Therapeutics, 27(3), 327-335. [CrossRef]
22. Culy, C.R., Clemett, D. Wiseman, L.R. (2000). Oxaliplatin. Drugs, 60, 895-924. [CrossRef]
23. Irinotecan. In: Lexicomp online [database on the Internet). Hudson [OH): Lexicomp, Inc.; 2021 [cited 18 Feb 2021). Available from: http://online.lexi.com. Subscription required to view.
24. Medscape Web site. (2022). Retrieved April 17, 2022, from https://reference.medscape.com/ drug/camptosar-irinotecan-342252#3. Accessed Date: 17.04.2022
25. Oxaliplatin. In: Lexicomp online [database on the Internet). Hudson [OH): Lexicomp, Inc.; 2021 [cited 18 Feb 2021). Available from: http://online.lexi.com. Subscription required to view.
26. Barlow, A., Prusak, E.S., Barlow, B., Nightingale, G. (2021). Interventions to reduce polypharmacy and optimize medication use in older adults with cancer. Journal of Geriatric Oncology, 12(6), 863-871. [CrossRef]
27. Bevacizumab. In: Lexicomp online [database on the Internet). Hudson [OH): Lexicomp, Inc.; 2021 [cited 18 Feb 2021). Available from: http://online.lexi.com. Subscription required to view.
28. Medscape Web site. (2022). Retrieved April 17, 2022, from https://reference.medscape.com/ drug/avastin-mvasi-bevacizumab-342257#11. Accessed Date: 17.04.2022
29. Ziv-Aflibercept. In: Lexicomp online [database on the Internet). Hudson [OH): Lexicomp, Inc.; 2021 [cited 18 Feb 2021). Available from: http://online.lexi.com. Subscription required to view.
30. Medscape Web site. (2022). Retrieved April 17, 2022, from https://reference.medscape.com/ drug/zaltrap-ziv-aflibercept-999765#5. Accessed Date: 17.04.2022
31. Nivolumab. In: Lexicomp online [database on the Internet). Hudson [OH): Lexicomp, Inc.; 2021 [cited 18 Feb 2021). Available from: http://online.lexi.com. Subscription required to view.
32. Medscape Web site. (2022). Retrieved April 17, 2022, from https://reference.medscape.com/ drug/opdivo-nivolumab-999989#3. Accessed Date: 17.04.2022
33. Pembrolizumab. In: Lexicomp online [database on the Internet). Hudson [OH): Lexicomp, Inc.; 2021 [cited 18 Feb 2021). Available from: http://online.lexi.com. Subscription required to view.
34. Medscape Web site. (2022). Retrieved April 17, 2022, from https://reference.medscape.com/ drug/keytruda-pembrolizumab-999962. Accessed Date: 17.04.2022
35. Ramucirumab. In: Lexicomp online [database on the Internet). Hudson [OH): Lexicomp, Inc.; 2021 [cited 18 Feb 2021). Available from: http://online.lexi.com. Subscription required to view.
36. Medscape Web site. (2022). Retrieved April 17, 2022, from https://reference.medscape.com/ drug/cyramza-ramucirumab-999926. Accessed Date: 17.04.2022
37. Regorafenib. In: Lexicomp online [database on the Internet). Hudson [OH): Lexicomp, Inc.; 2021 [cited 18 Feb 2021). Available from: http://online.lexi.com. Subscription required to view.
38. Medscape Web site. (2022). Retrieved April 17, 2022, from https://reference.medscape.com/ drug/stivarga-regorafenib-999774#3. Accessed Date: 17.04.2022
39. Larotrectinib. In: Lexicomp online [database on the Internet). Hudson [OH): Lexicomp, Inc.; 2021 [cited 18 Feb 2021). Available from: http://online.lexi.com. Subscription required to view.
40. Medscape Web site. (2022). Retrieved April 17, 2022, from https://reference.medscape.com/ drug/vitrakvi-larotrectinib-1000260#3. Accessed Date: 17.04.2022
41. Dabrafenib. In: Lexicomp online [database on the Internet). Hudson [OH): Lexicomp, Inc.; 2021 [cited 18 Feb 2021). Available from: http://online.lexi.com. Subscription required to view.
42. Gazzé G. (2018). Combination therapy for metastatic melanoma: A pharmacist's role, drug interactions complementary alternative therapies. Melanoma Management, 5(2), MMT07. [CrossRef]
43. Yin, H., Wang, Z., Wang, X., Lv, X., Fan, X., Yan, M., Jia, Y., Jiang, L., Cao, J., Liu, Y. (2021). Inhibition of human UDP-glucuronosyltransferase enzyme by dabrafenib: implications for drug-drug interactions. Biomedical Chromatography: BMC, 35(11), e5205. [CrossRef]
44. Trametinib. In: Lexicomp online [database on the Internet). Hudson [OH): Lexicomp, Inc.; 2021 [cited 18 Feb 2021). Available from: http://online.lexi.com. Subscription required to view.
45. Medscape Web site. (2022). Retrieved April 17, 2022, from https://reference.medscape.com/ drug/mekinist-trametinib-999854#5. Accessed Date: 17.04.2022
46. Trifluridine and tipiracil. In: Lexicomp online [database on the Internet). Hudson [OH): Lexicomp, Inc.; 2021
47. Kopetz, S., Grothey, A., Yaeger, R., Cutsem, E.V., Desai, J., Yoshino, T., Wasan, H., Ciardiello, F., Loupakis, F., Hong, Y.S., Steeghs, N., Guren, T.K., Arkenau, H.T., Garcia-Alfonso, P., Pfeiffer, P., Orlov, S., Lonardi, S., Elez, E., Kim, T.W., Schellens, J.H.M., Guo, C., Krishnan, A., Dekervel, J., Morris, V., Aitana Calvo Ferrandiz, A.C., Tarpgaard, L.S., Braun, M., Gollerkeri, A., Keir, C., Maharry, K., Pickard, M., Christy-Bittel J., Anderson, L., Sandor, V., Josep, T. (2019) Encorafenib, binimetinib, and cetuximab in BRAFV600E-mutated colorectal cancer. The New England Journal of Medicine, 381(17), 1632-1643. [CrossRef]
48. Tabernero, J., Grothey, A., Van Cutsem, E., Yaeger, R., Wasan, H., Yoshino, T., Desai, J., Ciardiello, F., Loupakis, F., Hong, Y.S., Steeghs, N., Guren, T.K., Arkenau, H.T., Garcia-Alfonso, P., Elez, E., Gollerkeri, A., Maharry, K., Christy-Bittel, J., Kopetz, S. (2021). Encorafenib plus cetuximab as a new standard of care for previously treated BRAF V600E-mutant metastatic colorectal cancer: updated survival results and subgroup analyses from the BEACON study. Journal of Clinical Oncology: official journal of the American Society of Clinical Oncology, 39(4), 273-284. [CrossRef]
49. Encorafenib. In: Lexicomp online [database on the Internet). Hudson [OH): Lexicomp, Inc.; 2021 [cited 19 Nov 2021). Available from: http://online.lexi.com. Subscription required to view.
50. Moghaddas, A., Adib-Majlesi, M., Sabzghabaee, A.M., Hajigholami, A., Riechelmann, R. (2021). Potential drug-drug İnteractions in hospitalized cancer patients: a report from the Middle-East. Journal of Oncology Pharmacy Practice: Official publication of the International Society of Oncology Pharmacy Practitioners, 27(1), 46-53. [CrossRef]
51. Mouzon, A., Kerger, J., D'Hondt, L., Spinewine, A. (2013). Potential interactions with anticancer agents: a cross-sectional study. Chemotherapy, 59(2), 85-92. [CrossRef]
52. Venkatesh, K.M., Swathi, A., Rajendra, H. (2021) Assessment of potential drug-drug interaction among the patients receiving cancer chemotherapy: a cross-sectional study. Journal of Pharmacology and Pharmacotherapeutics, 12(2), 79-85. [CrossRef]

APA	tezcan s (2022). MANAGEMENT OF DRUG INTERACTIONS IN COLON CANCER PATIENTS. , 537 - 550. 10.33483/jfpau.1039307
Chicago	tezcan songül MANAGEMENT OF DRUG INTERACTIONS IN COLON CANCER PATIENTS. (2022): 537 - 550. 10.33483/jfpau.1039307
MLA	tezcan songül MANAGEMENT OF DRUG INTERACTIONS IN COLON CANCER PATIENTS. , 2022, ss.537 - 550. 10.33483/jfpau.1039307
AMA	tezcan s MANAGEMENT OF DRUG INTERACTIONS IN COLON CANCER PATIENTS. . 2022; 537 - 550. 10.33483/jfpau.1039307
Vancouver	tezcan s MANAGEMENT OF DRUG INTERACTIONS IN COLON CANCER PATIENTS. . 2022; 537 - 550. 10.33483/jfpau.1039307
IEEE	tezcan s "MANAGEMENT OF DRUG INTERACTIONS IN COLON CANCER PATIENTS." , ss.537 - 550, 2022. 10.33483/jfpau.1039307
ISNAD	tezcan, songül. "MANAGEMENT OF DRUG INTERACTIONS IN COLON CANCER PATIENTS". (2022), 537-550. https://doi.org/10.33483/jfpau.1039307

APA	tezcan s (2022). MANAGEMENT OF DRUG INTERACTIONS IN COLON CANCER PATIENTS. Ankara Üniversitesi Eczacılık Fakültesi Dergisi, 46(2), 537 - 550. 10.33483/jfpau.1039307
Chicago	tezcan songül MANAGEMENT OF DRUG INTERACTIONS IN COLON CANCER PATIENTS. Ankara Üniversitesi Eczacılık Fakültesi Dergisi 46, no.2 (2022): 537 - 550. 10.33483/jfpau.1039307
MLA	tezcan songül MANAGEMENT OF DRUG INTERACTIONS IN COLON CANCER PATIENTS. Ankara Üniversitesi Eczacılık Fakültesi Dergisi, vol.46, no.2, 2022, ss.537 - 550. 10.33483/jfpau.1039307
AMA	tezcan s MANAGEMENT OF DRUG INTERACTIONS IN COLON CANCER PATIENTS. Ankara Üniversitesi Eczacılık Fakültesi Dergisi. 2022; 46(2): 537 - 550. 10.33483/jfpau.1039307
Vancouver	tezcan s MANAGEMENT OF DRUG INTERACTIONS IN COLON CANCER PATIENTS. Ankara Üniversitesi Eczacılık Fakültesi Dergisi. 2022; 46(2): 537 - 550. 10.33483/jfpau.1039307
IEEE	tezcan s "MANAGEMENT OF DRUG INTERACTIONS IN COLON CANCER PATIENTS." Ankara Üniversitesi Eczacılık Fakültesi Dergisi, 46, ss.537 - 550, 2022. 10.33483/jfpau.1039307
ISNAD	tezcan, songül. "MANAGEMENT OF DRUG INTERACTIONS IN COLON CANCER PATIENTS". Ankara Üniversitesi Eczacılık Fakültesi Dergisi 46/2 (2022), 537-550. https://doi.org/10.33483/jfpau.1039307